HORIZON THERAPEUTICS PLC (HZNP) Stock Fundamental Analysis
USA - NASDAQ:HZNP - IE00BQPVQZ61 - Common Stock
116.3 USD
+0.05 (+0.04%)
116.34 USD
+0.04 (+0.03%)
Taking everything into account, HZNP scores 6 out of 10 in our fundamental rating. HZNP was compared to 540 industry peers in the Biotechnology industry. HZNP scores excellent points on both the profitability and health parts. This is a solid base for a good stock. HZNP is not valued too expensively and it also shows a decent growth rate. This makes HZNP very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year HZNP was profitable.
In the past year HZNP had a positive cash flow from operations.
HZNP had positive earnings in 4 of the past 5 years.
Each year in the past 5 years HZNP had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 4.71%, HZNP belongs to the best of the industry, outperforming 95.21% of the companies in the same industry.
Looking at the Return On Equity, with a value of 8.25%, HZNP belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
HZNP has a better Return On Invested Capital (5.35%) than 95.87% of its industry peers.
The Average Return On Invested Capital over the past 3 years for HZNP is significantly below the industry average of 15.95%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROIC | 5.35% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
1.3 Margins
The Profit Margin of HZNP (12.02%) is better than 96.04% of its industry peers.
In the last couple of years the Profit Margin of HZNP has declined.
With an excellent Operating Margin value of 15.58%, HZNP belongs to the best of the industry, outperforming 96.53% of the companies in the same industry.
In the last couple of years the Operating Margin of HZNP has grown nicely.
Looking at the Gross Margin, with a value of 75.21%, HZNP belongs to the top of the industry, outperforming 84.49% of the companies in the same industry.
In the last couple of years the Gross Margin of HZNP has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% |
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so HZNP is destroying value.
Compared to 1 year ago, HZNP has about the same amount of shares outstanding.
HZNP has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.10 indicates that HZNP is not in any danger for bankruptcy at the moment.
HZNP has a Altman-Z score of 5.10. This is amongst the best in the industry. HZNP outperforms 81.35% of its industry peers.
HZNP has a debt to FCF ratio of 2.67. This is a good value and a sign of high solvency as HZNP would need 2.67 years to pay back of all of its debts.
The Debt to FCF ratio of HZNP (2.67) is better than 95.54% of its industry peers.
HZNP has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
HZNP has a Debt to Equity ratio of 0.48. This is in the lower half of the industry: HZNP underperforms 74.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Altman-Z | 5.1 |
ROIC/WACC0.75
WACC7.16%
2.3 Liquidity
A Current Ratio of 4.27 indicates that HZNP has no problem at all paying its short term obligations.
HZNP's Current ratio of 4.27 is in line compared to the rest of the industry. HZNP outperforms 41.58% of its industry peers.
HZNP has a Quick Ratio of 4.09. This indicates that HZNP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 4.09, HZNP is in line with its industry, outperforming 40.92% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 |
3. Growth
3.1 Past
The earnings per share for HZNP have decreased strongly by -19.39% in the last year.
HZNP shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 33.01% yearly.
HZNP shows a decrease in Revenue. In the last year, the revenue decreased by -4.42%.
Measured over the past years, HZNP shows a very strong growth in Revenue. The Revenue has been growing by 28.00% on average per year.
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
3.2 Future
The Earnings Per Share is expected to grow by 15.92% on average over the next years. This is quite good.
Based on estimates for the next years, HZNP will show a quite strong growth in Revenue. The Revenue will grow by 9.94% on average per year.
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
HZNP is valuated quite expensively with a Price/Earnings ratio of 25.90.
HZNP's Price/Earnings ratio is rather cheap when compared to the industry. HZNP is cheaper than 95.54% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.30. HZNP is around the same levels.
With a Price/Forward Earnings ratio of 20.14, HZNP is valued on the expensive side.
96.53% of the companies in the same industry are more expensive than HZNP, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.73. HZNP is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 |
4.2 Price Multiples
94.88% of the companies in the same industry are more expensive than HZNP, based on the Enterprise Value to EBITDA ratio.
96.37% of the companies in the same industry are more expensive than HZNP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 27.79 | ||
| EV/EBITDA | 27.94 |
4.3 Compensation for Growth
HZNP has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.78
EPS Next 2Y8.89%
EPS Next 3Y11.9%
5. Dividend
5.1 Amount
HZNP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
116.3
+0.05 (+0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners0.58%
Ins Owner Change0%
Market Cap26.63B
Analysts50.91
Price Target118.83 (2.18%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.7%
Min EPS beat(2)-27.35%
Max EPS beat(2)13.95%
EPS beat(4)3
Avg EPS beat(4)4.23%
Min EPS beat(4)-27.35%
Max EPS beat(4)21.5%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.41%
Min Revenue beat(2)-9.59%
Max Revenue beat(2)6.77%
Revenue beat(4)3
Avg Revenue beat(4)-0.15%
Min Revenue beat(4)-9.59%
Max Revenue beat(4)6.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.76%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 25.9 | ||
| Fwd PE | 20.14 | ||
| P/S | 7.31 | ||
| P/FCF | 27.79 | ||
| P/OCF | 25.59 | ||
| P/B | 5.01 | ||
| P/tB | 26.53 | ||
| EV/EBITDA | 27.94 |
EPS(TTM)4.49
EY3.86%
EPS(NY)5.77
Fwd EY4.97%
FCF(TTM)4.19
FCFY3.6%
OCF(TTM)4.54
OCFY3.91%
SpS15.92
BVpS23.19
TBVpS4.38
PEG (NY)N/A
PEG (5Y)0.78
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.71% | ||
| ROE | 8.25% | ||
| ROCE | 6.77% | ||
| ROIC | 5.35% | ||
| ROICexc | 7.58% | ||
| ROICexgc | 27.86% | ||
| OM | 15.58% | ||
| PM (TTM) | 12.02% | ||
| GM | 75.21% | ||
| FCFM | 26.3% |
ROA(3y)6.1%
ROA(5y)6.05%
ROE(3y)10.47%
ROE(5y)10.88%
ROIC(3y)6.68%
ROIC(5y)4.8%
ROICexc(3y)9.75%
ROICexc(5y)6.96%
ROICexgc(3y)39.54%
ROICexgc(5y)N/A
ROCE(3y)8.46%
ROCE(5y)6.07%
ROICexcg growth 3Y27.62%
ROICexcg growth 5YN/A
ROICexc growth 3Y33.99%
ROICexc growth 5YN/A
OM growth 3Y23.86%
OM growth 5YN/A
PM growth 3Y-31.18%
PM growth 5YN/A
GM growth 3Y1.14%
GM growth 5Y6.97%
F-Score6
Asset Turnover0.39
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.48 | ||
| Debt/FCF | 2.67 | ||
| Debt/EBITDA | 2.66 | ||
| Cap/Depr | 21.15% | ||
| Cap/Sales | 2.26% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 108.78% | ||
| Profit Quality | 218.81% | ||
| Current Ratio | 4.27 | ||
| Quick Ratio | 4.09 | ||
| Altman-Z | 5.1 |
F-Score6
WACC7.16%
ROIC/WACC0.75
Cap/Depr(3y)32.95%
Cap/Depr(5y)21.63%
Cap/Sales(3y)3.95%
Cap/Sales(5y)2.73%
Profit Quality(3y)169.09%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.39%
EPS 3Y34.76%
EPS 5Y33.01%
EPS Q2Q%12.15%
EPS Next Y-5.01%
EPS Next 2Y8.89%
EPS Next 3Y11.9%
EPS Next 5Y15.92%
Revenue 1Y (TTM)-4.42%
Revenue growth 3Y40.8%
Revenue growth 5Y28%
Sales Q2Q%7.82%
Revenue Next Year5.55%
Revenue Next 2Y9.53%
Revenue Next 3Y10.34%
Revenue Next 5Y9.94%
EBIT growth 1Y-37.19%
EBIT growth 3Y74.4%
EBIT growth 5YN/A
EBIT Next Year6.03%
EBIT Next 3Y14.62%
EBIT Next 5Y17.3%
FCF growth 1Y83.52%
FCF growth 3Y42.98%
FCF growth 5Y33.65%
OCF growth 1Y72.19%
OCF growth 3Y43.43%
OCF growth 5Y34.64%